CG Oncology, Inc. — Earnings Quality Grade F
CGON · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 254.7% but CFFO declined -68.1%
Expense Quality
Insufficient data
CapEx growth -42.7% vs revenue 254.7%. Normal
SG&A/Gross Profit = -12113.0%, excellent (<30%)
Gross margin swung -115.0pp (100.0% → -15.0%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.1B)
Accruals ratio = -3.6%. Low accruals
Cash $0.7B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
Debt/EBITDA = -0.0x. Healthy
Other assets grew 1685.1% vs revenue 254.7%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
Insufficient data
Manipulation Score
Calculation error: float division by zero
Portfolio monitoring
Monitor CGON continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25